TY - JOUR
T1 - Particulate and drug-induced toxicity assessed in novel quadruple cell human primary hepatic disease models of steatosis and pre-fibrotic NASH
AU - Kermanizadeh, Ali
AU - Valli, Jessica
AU - Sanchez, Katarzyna
AU - Hutter, Simon
AU - Pawlowska, Agnieszka
AU - Whyte, Graeme
AU - Moritz, Wolfgang
AU - Stone, Vicki
N1 - Funding Information:
This work has been financially supported by H2020 funded project PATROLS [Grant code—760813], EU Tox-Risk [Grant code—681002] and SULSA Technology seed funding grant.
Funding Information:
The authors are grateful to colleagues at the University of Derby, InSphero and Heriot Watt University. The fluorescence imaging experiments were conducted using the facilities provided by the Edinburgh Super-Resolution Imaging Consortium (ESRIC) at Heriot-Watt University.
Publisher Copyright:
© 2021, The Author(s).
PY - 2022/1
Y1 - 2022/1
N2 - In an effort to replace, reduce and refine animal experimentation, there is an unmet need to advance current in vitro models that offer features with physiological relevance and enhanced predictivity of in vivo toxicological output. Hepatic toxicology is key following chemical, drug and nanomaterials (NMs) exposure, as the liver is vital in metabolic detoxification of chemicals as well as being a major site of xenobiotic accumulation (i.e., low solubility particulates). With the ever-increasing production of NMs, there is a necessity to evaluate the probability of consequential adverse effects, not only in health but also in clinically asymptomatic liver, as part of risk stratification strategies. In this study, two unique disease initiation and maintenance protocols were developed and utilised to mimic steatosis and pre-fibrotic NASH in scaffold-free 3D liver microtissues (MT) composed of primary human hepatocytes, hepatic stellate cells, Kupffer cells and sinusoidal endothelial cells. The characterized diseased MT were utilized for the toxicological assessment of a panel of xenobiotics. Highlights from the study included: 1. Clear experimental evidence for the pre-existing liver disease is important in the augmentation of xenobiotic-induced hepatotoxicity and 2. NMs are able to activate stellate cells. The data demonstrated that pre-existing disease is vital in the intensification of xenobiotic-induced liver damage. Therefore, it is imperative that all stages of the wide spectrum of liver disease are incorporated in risk assessment strategies. This is of significant consequence, as a substantial number of the general population suffer from sub-clinical liver injury without any apparent or diagnosed manifestations.
AB - In an effort to replace, reduce and refine animal experimentation, there is an unmet need to advance current in vitro models that offer features with physiological relevance and enhanced predictivity of in vivo toxicological output. Hepatic toxicology is key following chemical, drug and nanomaterials (NMs) exposure, as the liver is vital in metabolic detoxification of chemicals as well as being a major site of xenobiotic accumulation (i.e., low solubility particulates). With the ever-increasing production of NMs, there is a necessity to evaluate the probability of consequential adverse effects, not only in health but also in clinically asymptomatic liver, as part of risk stratification strategies. In this study, two unique disease initiation and maintenance protocols were developed and utilised to mimic steatosis and pre-fibrotic NASH in scaffold-free 3D liver microtissues (MT) composed of primary human hepatocytes, hepatic stellate cells, Kupffer cells and sinusoidal endothelial cells. The characterized diseased MT were utilized for the toxicological assessment of a panel of xenobiotics. Highlights from the study included: 1. Clear experimental evidence for the pre-existing liver disease is important in the augmentation of xenobiotic-induced hepatotoxicity and 2. NMs are able to activate stellate cells. The data demonstrated that pre-existing disease is vital in the intensification of xenobiotic-induced liver damage. Therefore, it is imperative that all stages of the wide spectrum of liver disease are incorporated in risk assessment strategies. This is of significant consequence, as a substantial number of the general population suffer from sub-clinical liver injury without any apparent or diagnosed manifestations.
KW - 3D primary human quadruple-cell liver microtissue model
KW - In vitro hepatotoxicity
KW - In vitro vs. in vivo relevance
KW - NASH
KW - Pre-existing disease state
KW - Steatosis
UR - http://www.scopus.com/inward/record.url?scp=85117346856&partnerID=8YFLogxK
U2 - 10.1007/s00204-021-03181-2
DO - 10.1007/s00204-021-03181-2
M3 - Article
C2 - 34668024
SN - 0340-5761
VL - 96
SP - 287
EP - 303
JO - Archives of Toxicology
JF - Archives of Toxicology
IS - 1
ER -